Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy
Seeking Alpha ·
Shares of Arcturus Therapeutics ( ARCT ) climbed on Thursday after the messenger RNA medicines company announced a partnership with Thermo Fisher Scientific ( TMO ) to advance ARCT-032, its experimental therapy for the genetic disorder cystic fibrosis.
DYAX Investor Sentiment
Bullish (Long) 34% · Bearish (Short) 66%
293 participants
Related News
- 3 Core Artificial Intelligence (AI) Market Leaders to Buy with $1,000 Right Now and Hold for the Next 20 Years
- SA Asks: What's next for telecommunications stocks?
- Meta Could Hand Samsung Its Biggest AI Chip Order Yet in $6.5 Billion Deal
- Meta's AI Payoff Timeline Looks Messier
- Citi's Blockchain Pre-IPO Platform Trades Liquidity for Privacy, Polygon's Marc Boiron Says
- Why the Supreme Court's Ruling on the Fed This Week Is Good for the Stock Market